AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $208.98 billion. The enterprise value is $236.17 billion.
| Market Cap | 208.98B |
| Enterprise Value | 236.17B |
Important Dates
The last earnings date was Tuesday, April 29, 2025, before market open.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | Feb 21, 2025 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 13.54 and the forward PE ratio is 14.49.
| PE Ratio | 13.54 |
| Forward PE | 14.49 |
| PS Ratio | 3.80 |
| Forward PS | 4.70 |
| PB Ratio | 5.08 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.74 |
| P/OCF Ratio | 15.97 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.92, with an EV/FCF ratio of 21.18.
| EV / Earnings | 30.39 |
| EV / Sales | 4.30 |
| EV / EBITDA | 12.92 |
| EV / EBIT | 17.35 |
| EV / FCF | 21.18 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.77.
| Current Ratio | 0.90 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | 2.84 |
| Interest Coverage | 10.16 |
Financial Efficiency
Return on equity (ROE) is 19.79% and return on invested capital (ROIC) is 11.73%.
| Return on Equity (ROE) | 19.79% |
| Return on Assets (ROA) | 8.16% |
| Return on Invested Capital (ROIC) | 11.73% |
| Return on Capital Employed (ROCE) | 17.65% |
| Revenue Per Employee | $583,054 |
| Profits Per Employee | $82,418 |
| Employee Count | 94,300 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.72 |
Taxes
In the past 12 months, AstraZeneca has paid $1.51 billion in taxes.
| Income Tax | 1.51B |
| Effective Tax Rate | 16.26% |
Stock Price Statistics
The stock price has decreased by -11.82% in the last 52 weeks. The beta is 0.18, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -11.82% |
| 50-Day Moving Average | 72.10 |
| 200-Day Moving Average | 73.40 |
| Relative Strength Index (RSI) | 40.16 |
| Average Volume (20 Days) | 5,454,654 |
Short Selling Information
The latest short interest is 6.33 million, so 0.20% of the outstanding shares have been sold short.
| Short Interest | 6.33M |
| Short Previous Month | 10.60M |
| Short % of Shares Out | 0.20% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.97 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $54.98 billion and earned $7.77 billion in profits. Earnings per share was $4.97.
| Revenue | 54.98B |
| Gross Profit | 45.33B |
| Operating Income | 13.61B |
| Pretax Income | n/a |
| Net Income | 7.77B |
| EBITDA | 18.28B |
| EBIT | 13.61B |
| Earnings Per Share (EPS) | $4.97 |
Balance Sheet
The company has $5.40 billion in cash and $31.72 billion in debt, giving a net cash position of -$26.32 billion or -$16.98 per share.
| Cash & Cash Equivalents | 5.40B |
| Total Debt | 31.72B |
| Net Cash | -26.32B |
| Net Cash Per Share | -$16.98 |
| Equity (Book Value) | 41.13B |
| Book Value Per Share | 26.48 |
| Working Capital | -2.99B |
Cash Flow
In the last 12 months, operating cash flow was $13.09 billion and capital expenditures -$1.94 billion, giving a free cash flow of $11.15 billion.
| Operating Cash Flow | 13.09B |
| Capital Expenditures | -1.94B |
| Free Cash Flow | 11.15B |
| FCF Per Share | $7.19 |
Margins
Gross margin is 82.44%, with operating and profit margins of 24.75% and 14.14%.
| Gross Margin | 82.44% |
| Operating Margin | 24.75% |
| Pretax Margin | 16.90% |
| Profit Margin | 14.14% |
| EBITDA Margin | 33.24% |
| EBIT Margin | 24.75% |
| FCF Margin | 20.28% |
Dividends & Yields
This stock pays an annual dividend of $1.54, which amounts to a dividend yield of 2.29%.
| Dividend Per Share | $1.54 |
| Dividend Yield | 2.29% |
| Dividend Growth (YoY) | 6.21% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 30.99% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 2.21% |
| Earnings Yield | 3.72% |
| FCF Yield | 5.34% |
Analyst Forecast
The average price target for AstraZeneca is $92.33, which is 37.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $92.33 |
| Price Target Difference | 37.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 6.64% |
| EPS Growth Forecast (5Y) | 9.39% |
Stock Splits
The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
AstraZeneca has an Altman Z-Score of 3.08 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.08 |
| Piotroski F-Score | 7 |